Analyzing adverse event signals of aprepitant using FAERS database data in real-world settings: Broadening the adverse event spectrum of aprepitant and its clinical implications. [PDF]
Chen F, Cai D, Wen H, Zhang L.
europepmc +1 more source
Aprepitant use during chemotherapy and association with survival in women with early breast cancer. [PDF]
Botteri E +10 more
europepmc +1 more source
Comparison of aprepitant, dexamethasone, and ondansetron with dexamethasone and ondansetron for prevention of postoperative nausea and vomiting in high-risk patients undergoing laparoscopic surgeries: a randomized controlled trial in India. [PDF]
Bala S +5 more
europepmc +1 more source
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications. [PDF]
Boretti E, Dogné JM, Douxfils J.
europepmc +1 more source
Erratum in: Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant. [PDF]
europepmc +1 more source
Olanzapine Use and Vomiting Incidence in Chemotherapy-receiving Patients With Cervical Cancer: Multicenter Post Hoc Analysis. [PDF]
Kawamura Y +17 more
europepmc +1 more source
Aprepitant alleviates acute lung injury in a rat model of hepatic ischemia-reperfusion via NLRP3/IL-1β signaling pathway. [PDF]
Abdelzaher WY +5 more
europepmc +1 more source
Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study. [PDF]
Mehboob R +8 more
europepmc +1 more source
Three are better than two: redefining prophylaxis for postoperative nausea and vomiting. [PDF]
Kang H.
europepmc +1 more source
Exploring Potential Drug-Drug Interactions: A Cross-Sectional Study of 1 Million e-Prescriptions Across Medical Specialties in Shiraz, Iran (2021-2024). [PDF]
Porbaha P +5 more
europepmc +1 more source

